The 26S proteasome is the major proteolytic machine for breaking down cytosolic and nuclear proteins in eukaryotes. Due to the lack of a suitable assay, it is difficult to measure routinely and quantitatively, the breakdown of proteins by the 26S proteasome in vitro. In the present study, we developed an assay to monitor proteasome-mediated protein degradation. Using this assay, we discovered that epipolythiodioxopiperazines (ETPs) blocked the degradation of our model substrate in vitro. Further characterization revealed that ETPs inhibited proteasome function by targeting the essential proteasomal deubiquitinase Rpn11. ETPs also inhibited other JAMM proteases such as Csn5 and AMSH.
Introduction
The fungus Aspergillus fumigatus is one of the most common species to cause disease in immunocompromised individuals, such as AIDS patients and organ transplant recipients (Dolan, et al., 2015) . A. fumigatus infection causes aspergillosis and immunosuppression (Scharf, et al., 2016) . The secondary metabolites produced by Aspergillus are considered to be important virulence factors. Among them, gliotoxin, an epidithiodiketopiperazine (ETP), is the major and the most potent toxin (Scharf, et al., 2016) . Most of the biological activities of gliotoxin are derived from a pair of sulfur atoms that form an unusual, intramolecular disulfide bridge (Dolan, et al., 2015; Scharf, et al., 2016) . Gliotoxin poisons animal cells by inactivating multiple key enzymes through conjugation of their thiol groups. Known targets of gliotoxin include nuclear factor κB (NF-κB), NADPH oxidase, and glutaredoxin (Pahl, et al., 1996; Srinivasan, et al., 2006; Tsunawaki, et al., 2004) . Glutathione (GSH) is important for gliotoxin uptake and mediates its cytotoxicity in animal cells, as it reduces gliotoxin to convert it into the toxic dithiol form (Dolan, et al., 2015) . Further studies have revealed a mechanism for its inhibition involving Zinc chelation: gliotoxin and other ETPs can inhibit HIF1α interaction with p300 by ejecting the Zn 2+ from p300 through the formation of a Zn 2+ -ETP complex (Cook, et al., 2009 ). This disrupts HIF1α activation and provides a plausible molecular basis for the anti-angiogenesis effects of ETPs.
The proteasome, the major cellular machine for protein degradation, is also reported as a target of gliotoxin (Kroll, et al., 1999) . Proteasomes are essential for various cellular processes including protein quality control, regulation of gene expression, and cell cycle progression. Structurally, the proteasome is composed of a 20S core particle (CP) and 19S regulatory particles (RP), which cap the ends of the CP. The RP recognizes polyubiquitinated substrates and processes them for insertion into the CP which contains the proteolytic active sites (Finley, 2009 ). There are three distinct catalytic peptidase activities identified in the CP: chymotrypsin-like, trypsin-like, and caspase-like (Heinemeyer, et al., 1997) . Drugs such as bortezomib and carfilzomib, which inhibit the active sites in the CP, are important therapeutic agents for the treatment of multiple myeloma (Dimopoulos, et al., 2015) . However, patients ultimately suffer relapse despite the clinical benefit conferred by these drugs. Therefore, novel drugs working through different mechanisms are needed. Recently, we and others discovered small molecule inhibitors targeting Rpn11, a JAMM protease that removes polyubiquitin chains from substrate proteins (Lauinger, et al., 2017; Li, et al., 2017; Perez, et al., 2017) . Inhibition of Rpn11 function results in proteasome malfunction and leads to cell death .
Previous research suggests that gliotoxin is a noncompetitive inhibitor of the chymotrypsin-like activity of the 20S proteasome (Kroll, et al., 1999) . However, the detailed mechanism of this inhibition remains unknown.
Herein, we developed an assay to measure the protein breakdown activity of the proteasome in purified systems and cell extracts and identified ETPs as a novel scaffold for inhibiting JAMM proteases. ETPs inhibit proteasome function by targeting the essential proteasomal deubiquitinase Rpn11. Identification of ETPs provides an alternative route to inhibit proteasome function and opens the door to the development of novel Rpn11 inhibitors.
Results

Development of a proteasome substrate to monitor protein degradation in vitro
There is no quantitative method for the simple and rapid assessment of 26S proteasome protein degradation activity in vitro to date. The Suc-LLVY-amc substrate widely used for the evaluation of 20S proteasome activity does not accurately reflect protein breakdown because it only measures the chymotrypsin-like active site of the β5 subunit. Meanwhile, it has been shown that to block protein degradation, it is necessary to inhibit both the chymotryptic site, which is intrinsically the most sensitive to the commonly used 20S inhibitors, as well as either the tryptic or caspase site, which are about an order of magnitude less sensitive (Demo, et al., 2007; Kisselev and Goldberg, 2005) . In addition, Suc-LLVY-amc is not only cleaved by the 20S proteasome but also by other chymotrypsin-like proteases and by calpains (Giguere and Schnellmann, 2008) .
To measure protein breakdown by the proteasome, we modified an existing method (Kim and Huibregtse, 2009) to generate a polyubiquitinated protein substrate, termed Ub n GST-Wbp2 (WW domain-binding protein 2, n>30) using enzymatic approaches ( Fig. 1A and Fig.   S1A ). Wbp2 was originally isolated from a mouse embryo library. It contains an N-terminal pleckstrin homology-glucosyltransferase (GRAM) domain and three C-terminal PPxY motifs, which interact with multiple WW domain-containing proteins (Chen and Sudol, 1995) . A previous study showed that Wbp2 functions as a coactivator for estrogen receptor and is closely linked to the development of breast cancer (Chen, et al., 2017) . The original method described by Huibregtse and colleagues relies on Rsp5-mediated ubiquitination of a truncated Wbp2 (Kim and Huibregtse, 2009 ). We modified their method by inserting a Cterminal hexahistidine tag into the GST-Wbp2 construct and chemically labeling the purified protein with a cysteine-reactive fluorophore. Rsp5 assembles K63-linked ubiquitin chains and contains a WW-domain that recognizes the PPxY motifs in Wbp2. Swapping the HECT domain of Rsp5 with that from E6AP yields a chimeric enzyme that preferentially synthesizes K48-linked ubiquitin chains (Kim and Huibregtse, 2009 ). The ubiquitin linkages formed on our substrate treated with the wild-type and chimeric Rsp5 were quantified by mass spectrometry. 87% of the linkages formed by Rsp5 were via K63 ( K63 Ub n GST-Wbp2), whereas 94% of those formed by the Rsp5-E6AP chimera were via K48 ( K48 Ub n GST-Wbp2; Table S1 ).
To test whether K63 Ub n GST-Wbp2 and K48 Ub n GST-Wbp2 were proteasome substrates, we incubated them with purified human 26S proteasomes and ATP, and analyzed the reactions by SDS-PAGE. The fluorescence-scanned gel showed that both proteins were degraded, consistent with the prior report (Kim and Huibregtse, 2009 ). The degradation was specific and was blocked by an Rpn11 inhibitor (capzimin, CZM), a 20S inhibitor (carfilzomib, CFZ) or a non-hydrolysable ATP analogue, AMP-PNP ( Fig. 1B and Fig. S1B ).
To simplify and accelerate data acquisition, we adapted the degradation assay to a format compatible with high throughput screening by monitoring the decrease in fluorescence polarization (FP) in a multi-well plate reader. The decreased fluorescence polarization indicated that the fluorescent Ub n GST-Wbp2 substrate was cleaved into smaller species.
Substrate degradation monitored in this fashion was specific in that it was inhibited by addition of 20S and Rpn11 inhibitors ( Fig. 1C and Fig. S1C-D) , or the slowly hydrolysable ATP analogue ATPγS (Fig. S1C ), and was competed by a large excess of K48-linked Ub 4 chains ( Fig. S1E ). Note that inhibition of the decrease in FP by the 20S inhibitor was not as complete as with the Rpn11 inhibitor ( Fig. 1C ), because there remained some decrease in FP due to substrate deubiquitination, which decreased its molecular weight ( Fig. 1B) .
To test whether the FP assay could be used to measure 26S proteasome activity directly in cell lysate, we lysed HEK293T cells treated with different concentrations of carfilzomib and performed the assay directly in the lysate by adding K48 Ub n GST-Wbp2 substrate and ATP.
Ubiquitin aldehyde was included in the assay buffer to eliminate the interference of cysteine-based deubiquitinases (Hershko and Rose, 1987) . The IC50 for inhibition of K48 Ub n GST-Wbp2 degradation by carfilzomib was 110 nM, which was ~20 fold higher than the IC50 obtained in the Suc-LLVY-amc assay (Fig. 1D ). This is consistent with the observation that inhibition of protein breakdown requires blockade of at least two of the three active sites (Kisselev and Goldberg, 2005) . This assay is also compatible with lysate prepared directly from tissue. In a recent study, we demonstrated that overexpression of the 11S proteasome subunit PA28 in the mouse retina does not alter ubiquitin-dependent protein degradation (Lobanova, et al., 2018) . This example illustrates how our assay can be used to monitor 26S proteasome activity in various disease states. It is worth noting that the K63 Ub n GST-Wbp2 substrate was not suitable for use in cell lysate, possibly due to the presence of a high level of K63 linkage-specific deubiquitinases (Cooper, et al., 2009) ( Fig. S1F ).
Epidithiodiketopiperazines (ETPs) block protein degradation
Gliotoxin is the most well-known member of the family of epidithiodiketopiperazine compounds. Previous reports indicated that it functions as a 20S proteasome inhibitor targeting chymotrypsin-like activity, and the inhibitory effect depends on an intact disulfide bond in gliotoxin (Kroll, et al., 1999) . However, gliotoxin exists almost exclusively in the dithiol form after uptake into cells due to the reducing power of cellular glutathione (Bernardo, et al., 2003) . These contradictory observations motivated us to revisit the interaction between ETPs and the proteasome.
Taking advantage of our newly designed FP assay, we investigated the effects of gliotoxin and its core scaffold compound, SOP6, on the proteasome-mediated degradation of K48 Ub n GST-Wbp2 ( Fig. 2A ). Both SOP6 and gliotoxin slowed down the decline in fluorescence polarization, suggesting that ETP compounds inhibited proteasome function.
To test this hypothesis, we treated HCT116 cells with different ETP compounds and immunoblotted for the accumulation of poly-ubiquitinated species. Gliotoxin and ETP analogues led to the accumulation of ubiquitinated species, which is a commonly used marker for proteasome inhibition (Fig. 2B) . In addition, we tested ETP compounds in a Ub G76V -GFP degradation assay (Chou and Deshaies, 2011) . The results indicated that multiple ETP compounds blocked the degradation of pre-accumulated Ub G76V -GFP, suggesting inhibitory effects on proteasome function (Table S2 ). Taken together, these results suggested that ETPs interfered with proteasome function in vitro and in cells. To identify the target of ETPs on the proteasome, we first examined their effects on the chymotrypsin-like activity of the 20S proteasome using the Suc-LLVY-amc fluorescence assay. Neither SOP6 nor gliotoxin showed inhibition of the chymotrypsin-like activity, indicating that reduced ETPs did not work as 20S proteasome inhibitors (Fig. 2C ). Given that gliotoxin exists exclusively in the reduced form in cells (Bernardo, et al., 2003) , it is most likely that ETPs inhibit the proteasome through another mechanism.
ETPs inhibit Rpn11 and other JAMM proteases
Chetomin is an ETP that was initially identified as a toxic secondary metabolite from fungi (Geiger, 1949) . Interestingly, chetomin was identified as the single positive hit in an HTS campaign for inhibitors that target the interaction between HIF1α and it coactivators p300 and CREB-binding protein (Kung, et al., 2004) . Subsequent research revealed that ETPs block the HIF1α-p300 interaction by extracting the zinc ion from the cysteine/histidinerich domain 1 (CH1) of p300 (Cook, et al., 2009 ).
The ubiquitin isopeptidase Rpn11 is the only essential proteasome subunit that is known to be zinc-dependent. Therefore, we surmised that ETPs might function as proteasome inhibitors by targeting Rpn11. To test this hypothesis, we evaluated the effect of ETPs on JAMM domain proteases and other metalloproteases ( Fig. 3A , Table 1 and Table S2 ). The results suggested that ETPs specifically inhibited JAMM proteases, although the tested compounds did not show selectivity between different members of the JAMM family (Table   1 and Table S2 ). We further confirmed that ETPs not only inhibited Rpn11 function in the context of the intact proteasome ( Fig. 3A ) but also directly inhibited di-Ub cleavage mediated by purified Rpn11•Rpn8 heterodimer (Fig. 3B ).
The dithiol/disulfide is required for the inhibitory effects of ETPs against HIF1α (Cook, et al., 2009) . Consistent with this, disrupting the disulfide bond in SOP7 completely abolished inhibitory activity towards Rpn11 (Table S2 ). We showed previously that compounds that inhibit Rpn11 via binding of zinc can be counteracted by the zinc coordination compound Zn(cyclen) 2+ , which titrates the inhibitor Perez, et al., 2017) . Zn(cyclen) 2+ shifted the IC50 value of SOP6 from 1.2 μM to 28 μM, which implied that ETPs inhibited Rpn11 activity by chelating the catalytic Zn 2+ ion (Fig. 3A ). In addition, ZnSO 4 added to cell culture medium blunted the effect of gliotoxin on Ub-conjugate accumulation (Fig. 3C ). We conclude that ETPs inhibit proteasome function by targeting JAMM protease Rpn11 via binding to its catalytic zinc ion.
Cellular effects of ETPs
Gliotoxin, the most well-studied ETP, has multiple cellular effects such as perturbation of microfilament structure and induction of cell detachment (Jordan and Pedersen, 1986 ).
However, cell detachment was not observed upon proteasome inhibition by either the Rpn11 inhibitor capzimin or the 20S proteasome inhibitor bortezomib ( Fig. S2 ). Therefore, cell detachment is likely due to an effect of gliotoxin on a target other than Rpn11. To test whether this effect can be diminished through medicinal chemistry optimization, we monitored cell detachment induced by twelve different ETPs. Among them, SOP10 and SOP11 did not detach cells but retained inhibitory activity towards Rpn11 (Fig. 2B, Fig. 4A and Table 1) . A previous study suggested that Rpn11 inhibition triggers a stress response that affects transcription (Lauinger, et al., 2017) . We therefore assessed the impact of SOP10 and SOP11 on transcription by monitoring highly unstable c-Myc mRNA in HCT116 cells. The level of c-Myc mRNA decreased upon treatment with these compounds, indicating negative effects of ETPs on transcription (Fig. 4B ). Gliotoxin was reported to inhibit the activity of HOIP, a component of the linear ubiquitin chain assembly complex that mediates activation of IκB kinase (Sakamoto, et al., 2015) . We therefore tested the effect of ETPs on the degradation of IκB induced by TNF-α stimulation. Gliotoxin and chetomin strongly stabilized IκB and SOP6 and SOP8 slightly stabilized IκB, but other ETPs showed no effects on IκB degradation (Fig. S3 ).
To evaluate the impact of ETPs on proteasome function in cells in more detail, we evaluated the degradation of two endogenous proteasome substrates, NFE2L1 and NFE2L2. Nuclearfactor-erythroid-derived-2-related factor 1 (NFE2L1) is an unstable transcription factor that regulates the expression of genes that encode proteasome subunits. Upon inhibition of the proteasome, a processed form of NFE2L1 accumulates and induces transcription of proteasome subunit genes (Radhakrishnan, et al., 2010; Steffen, et al., 2010) . Multiple ETPs including SOP10 and SOP11 mimicked capzimin and induced accumulation of processed NFE2L1 (Fig. 4C) . Similarly, NFE2L2, the transcription factor that regulates antioxidant response, also accumulated after treatment with ETPs ( Fig. 4C ). We also examined other endogenous proteasome substrates including c-Myc, p53 and MDM2. ETPs showed little effect on those substrates (Fig. S4) , which could be due to the negative impact of those compounds on transcription (Fig. 2B) , weak potency in cells, or different substrate profiles from the conventional 20S proteasome inhibitors. Notably, the cell-detaching compounds SOP6 and gliotoxin caused accumulation of Nedd8-conjugated Cul1, whereas SOP10 and SOP11 did not (Fig. 4C ). This suggests that SOP10 and SOP11 do not appreciably inhibit the JAMM enzyme Csn5 in cells.
Previous studies revealed that Rpn11 inhibition triggered an unfolded protein response (UPR) . Surprisingly, only SOP11 provoked a pronounced UPR in cells, as determined by the accumulation of phosphorylated protein kinase R-like endoplasmic reticulum kinase (PERK), spliced X-box binding protein 1 (XBP1s), the transcription factor CCAAT/enhancer-binding protein homologous protein (CHOP) and Binding immunoglobulin protein (BiP) (Fig. 4D ). Little UPR response was triggered by SOP10, which is in agreement with its weaker effects on the clearance of accumulated Ub G76V GFP and high GI50 on cell proliferation (Table S2 ) . Based on all of the results summarized above, we conclude that SOP11 is the most promising candidate for a selective Rpn11 inhibitor among the tested ETPs.
SOP11 blocks cancer cell proliferation
Inhibition of proteasome function results in cell death, which underlies the activity of the 'omibs' in chemotherapy of multiple myeloma. We and others previously showed that chemical inhibition of Rpn11 blocks cancer cell proliferation Song, et al., 2017) . We measured the effects of ETPs on the proliferation of HCT116 human colon cancer cells and calculated inhibition of cell growth (GI50) ( Table S2 ). SOP6 was the most potent growth inhibitor. However, as exemplified by its effects on cell detachment, it may work through inhibiting multiple cellular targets in addition to Rpn11. The more selective compound SOP11 inhibited cell proliferation with a GI50 value of ~4.7 μM (Table 1) . Of relevance to the potential for targeting Rpn11 in 'omib' refractory myeloma patients, we tested SOP11 using WT and bortezomib-resistant (BTZ R ) retinal pigment epithelial (RPE) cells (Wacker, et al., 2012) . SOP11 had the same GI50 against WT and BTZ R RPE cells (~8 μM; Fig. 5A ), indicating that ETP-based and 'omib' inhibitors worked through distinct mechanisms. In addition to inhibiting cell growth, ETPs induced cell apoptosis, as confirmed by immunoblotting for caspase-cleaved poly (ADP-ribose) polymerase (PARP1) ( Fig. 5B) . DNA damage is a common event during apoptosis, which is reflected by the increased phosphorylation of H2AX (γH2AX). ETPs strongly induced H2AX phosphorylation after 24 hours treatment, indicating the occurrence of the DNA damage response (Fig. 5B ).
Discussion
Gliotoxin is the most well-studied ETP. It targets multiple proteins and enzymes with important cellular functions. The proteasome, the central cellular machine for protein degradation, has been reported as a target of gliotoxin (Kroll, et al., 1999) . It inhibits the chymotrypsin-like activity of 20S proteasome at high concentrations under oxidative conditions. However, gliotoxin is rapidly reduced upon its uptake by the cell (Bernardo, et al., 2003) . We report here that multiple ETPs including gliotoxin inhibit the proteasome in vitro and in cells by targeting its essential deubiquitinase subunit Rpn11. Inhibition of Rpn11 function by gliotoxin and other ETPs led to proteasome malfunction and subsequent cell death. Our findings identify ETPs as a novel inhibitor scaffold for targeting Rpn11 and open the door to further development of more specific and potent Rpn11 inhibitors.
A key consideration in the characterization of novel inhibitors is their target specificity.
Whereas gliotoxin is one of the most potent ETPs for inhibiting the proteasome, it is also relatively non-selective and induces morphological changes in cells that are not observed with the selective Rpn11 inhibitor capzimin (Jordan and Pedersen, 1986) . To address this non-selectivity, we surveyed a panel of related molecules that share the core ETP scaffold and identified SOP11 as a candidate for future studies. Unlike gliotoxin, SOP11 did not cause the cell rounding phenotype. Like capzimin, SOP11 triggered an unfolded protein response and induced accumulation of polyubiquitin conjugates and the specific proteasome substrates NFE2L1 and NFE2L2. SOP11 also mimicked capzimin in that it did not inhibit zinc-dependent enzymes unrelated to Rpn11, such as human carbonic anhydrase and matrix metalloproteinase-2. However, SOP11 does inhibit other members of the JAMM family in vitro in addition to Rpn11, including Csn5 and AMSH. However, we did not observe effects on the Csn5 substrate Cul1 at concentrations of SOP11 that inhibited the proteasome. Thus, SOP11 is a promising starting point to develop Rpn11 inhibitors based on the ETP scaffold. However, considerable medicinal chemistry optimization will be required to generate ETPs that have sufficient potency and specificity to enable a rigorous test of the therapeutic potential of Rpn11 inhibition.
The proteasome is the central conduit through which all substrates of the ubiquitinproteasome system (UPS) are degraded. Genomic mutations, aneuploidy, and other alterations in cancer cells can result in an imbalance between protein expression and the degradative capacity of the UPS (Cenci, et al., 2008; Deshaies, 2014) . This has the potential to render cancer cells more dependent on proteasome activity than normal cells. Inhibitors targeting the proteolytic center of the 20S proteasome, such as bortezomib, carfilzomib, and ixazomib, have been approved for the treatment of multiple myeloma and mantle cell lymphoma, thereby validating the hypothesis that at least some cancer cells have heightened dependence on proteasome activity. However, proteasome inhibitor therapy has not been successfully expanded to the treatment of solid tumors, potentially due to reduced sensitivity of solid tumor cells to proteasome inhibitors coupled with the pharmacological properties of the existing drugs (Deshaies, 2014) . Our study provides an alternative to achieve proteasome inhibition, which might translate into a new therapeutic approach in the future.
Changes in proteasome activity have been suggested to occur during aging and in neurodegenerative diseases (Saez and Vilchez, 2014) . Proteasome dysfunction and decreased proteasome activity might contribute to aging-related diseases. For example, it has been proposed that toxic protein aggregates that accumulate in polyglutamine repeat diseases such as Huntington's Disease may inhibit proteasome function (Diaz-Hernandez, et al., 2006) , although this has been controversial (Hipp, et al., 2012; Ortega, et al., 2007) .
One problem in addressing the role of proteasome activity in aging and disease has been a lack of suitable assays to directly measure the protein breakdown activity of the proteasome in cell lysates. Consequently, these studies rely on measuring the chymotryptic peptidase activity of the β5 subunit, which shows poor correlation with protein breakdown activity (Bence, et al., 2001) . The new proteasome activity assay we developed in this study may help to shed light on these simple yet important issues. 
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Figure Legends
(C) HCT116 cells were treated for 6 hours with indicated compounds, and cell lysates were fractionated by SDS-PAGE and immunoblotted with antibodies against NFE2L1, NFE2L2, Rpn11, Cul1 and GAPDH (loading control for C and D). (D) Same as C, except that antibodies against XBP1, CHOP, PERK and Bip were used. See also Figure S2 , Figure S3 and Figure S4 . HCT116 cells were treated with 10 μM of the indicated ETPs or CZM for 24 hours. Western blot analyses of cell lysates were performed with antibodies against PARP1, γH2AX, and GAPDH, as indicated. See also Table S2 . 
METHOD DETAILS
Plasmid construction and protein purification. Purification of GST-Ube1 (E1), Rsp5 (E3 for generating K63-linked Ub chains) and Rsp5-E6AP (E3 for generating K48-linked Ub chains) was carried out as described previously (Kim and Huibregtse, 2009 ). UbcH5a ( In vitro ubiquitination and purification. To ubiquitinate GST-Wbp2-C-K222-His6, two separate mixtures (E3 + substrate and GST-Ube1+UbcH5a+ubiquitin+ATP) were preincubated for two minutes and then combined to initiate the reaction. Ubiquitination was carried out at room temperature for 4 hours. The reaction mixture was purified by Ni-NTA affinity chromatography and desalting chromatography to remove E1, E2 and E3 and exchange the buffer.
Chemical Syntheses. Details of chemical syntheses can be found in Methods S1.
SDS-PAGE analysis of proteasome activity. 20 nM Ub n GST-Wbp2 and 4 nM purified
human 26S proteasome were incubated at 37 ˚C for 2 hours in the presence of different compounds plus 1 mM ATP. The reactions were stopped with 2× SDS sample buffer and analyzed by SDS-PAGE. The gel was scanned using Typhoon™ FLA 9500 biomolecular imager (GE Healthcare life sciences) with filter for fluorophore Alexa 488.
Fluorescence polarization assay. The fluorescence polarization assay was performed in a low-volume 384-well solid black plate to which the components were added in the following sequence: 1) 5 µl compound in 3% (v/v) DMSO or 3% DMSO control, 2) 5 µl of 26S proteasome (Enzo life science), 3) 5 µl of 5 nM Ub n GST-Wbp2 to initiate the reaction.
Fluorescence polarization was measured using a plate reader with excitation at 480 nm and emission at 520 nm (PHERAstar, BMG Labtech). 
